Transmucosal Thin-Film Dosage Form for Rapid API Absorption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Patients, particularly those with swallowing difficulties or aversions, face challenges in administering oral medicaments due to issues such as pharyngeal motility problems, size, shape, taste, and psychological aversions, necessitating a need for a convenient and effective delivery method.
Innovation Solution
A unit dosage form for oral transmucosal delivery containing a therapeutically effective amount of an active pharmaceutical ingredient (API) and a permeation enhancer, which includes a PEG-derived ester of a fatty acid and a gas-producing component, facilitating rapid absorption through the sublingual and buccal mucosa.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If conventional solid dosage forms (pills, tablets, capsules) are used for oral administration, then the medicament can be delivered to the patient, but patients experience difficulty swallowing due to pharyngeal motility problems, size, shape, taste, or psychological aversion
Solution Approach 1:
The patent employs a thin film dosage form that dissolves on contact with salivary fluid in the oral cavity. This thin film approach eliminates the need for swallowing solid pills or tablets, directly addressing the swallowing difficulty problem while maintaining effective drug delivery through the oral mucosa
Solution Approach 2:
The patent changes the physical state and delivery mechanism of the medicament from solid oral administration to a dissolving thin film that releases drug through the oral mucosa. This parameter change transforms the administration process from requiring swallowing to requiring only placement in the mouth, eliminating the harmful effect of swallowing difficulty
2Productivity
If the API is delivered through conventional oral routes, then the medicament can be administered, but absorption is slow and bioavailability is limited
Solution Approach 1:
The patent uses permeation enhancers as intermediary substances that facilitate the transport of the API through the oral mucosa. These enhancers create channels or modify the mucosal barrier properties, enabling faster and more efficient drug absorption compared to conventional oral routes
Solution Approach 2:
The patent incorporates a gas-generating component that produces gas bubbles upon contact with salivary fluid. This gas generation creates a bubbling effect that enhances contact between the API and the oral mucosa, thereby accelerating absorption and reducing onset time
3Reliability
If permeation enhancers are added to the thin film formulation, then API permeability increases to at least 1.25 cm/h, but the formulation complexity increases
Solution Approach 1:
The patent creates a composite thin film formulation combining the API with permeation enhancers and gas-generating components. This composite approach integrates multiple functional elements (drug delivery, permeation enhancement, gas generation) into a single unified dosage form, achieving reliable permeability while managing formulation complexity through synergistic component selection
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables fast absorption and high bioavailability of the API, providing a rapid onset of action and improving patient compliance by circumventing swallowing difficulties.
Implementation Method 1
The permeation enhancer is in an effective amount to enable the API of the unit dosage form to reach a permeability coefficient of at least 1.25 cm/h as measured by the Franz Cell System using 0.45 μm Nylon as penetration media
Implementation Method 2
The permeation enhancer contains at least one of the following: (a) at least an ester of a fatty acid, wherein the permeation enhancer has a HLB value ranging from about 8 to about 10; and (b) a gas-producing component
Data Source
AI summary
A novel unit dosage form for oral transmucosal delivery of an active pharmaceutical ingredient (API). The dosage form contains a permeation enhancer that promotes fast absorption, rapid onset of action, and overall high bio availability for the API.